Embed Size (px)
Citation preview
Society of Investment Professionals in Germany
Big Data in Healthcare
16 June 2015
DVFA Center, Frankfurt/Main
8th DVFA Life Science Conference
Supported by
Media PartnerSchnee Research
The 8th DVFA-Life Science Conference focuses on the challenges and opportunities of Big Data in Healthcare.
Big Data is currently one of the key strategic topics for regulators, health insurers and healthcare & life science companies. How to integrate the vast amount of data about gene variants, biomarkers, clinical outcomes and side effects in drug discovery, reim-bursement and clinical pathways? How to turn data into knowledge? Established and new players have developed solutions that help to collect, save, manage and interpret the gigantic data volume generated by independent researchers, healthcare compa-nies and academic institutions and new technologies such as Next Generation Sequencing. The smart use of "Big data" allows higher efficiency, effectiveness and quality in R&D, innovative personalized therapies and customized patient care solutions. The use of patient data enables better informed decisions but also raises political and ethical issues, that need to be addressed.
uTopics Deriving medical insights from Big Data - A project report across Healthcare and Life Sciences Matching patient genomes to treatment – challenges and opportunities for IT in personalized medicine Sequencing data without informatics? As valuable as a chocolate teapot! Panel discussion: Big Data for better Therapies Overview why Big data in healthcare is getting more important and examples how UCB is addressing this. A new telematic infrastructure in the German Healthcare system Analysis of patient data clouds to improve clinical therapies The Deutsche Börse Venture Network Panel discussion: Big Data in Healthcare at the Capital Markets
uSpeakers & Moderators Dr. Christa Bähr, CEFA, CFA, Founder and Business Owner, CB HealthCare Dr. Siegfried Bialojahn, Ernst & Young GmbH Dr. Stephan Brock, Chief Technology Officer (CTO), Molecular Health GmbH Kai Brüning, CEFA, Senior Portfolio Manager, apoAsset Management GmbH Martin Bumm, Prokurist, medisign GmbH Herman de Prins, CIO, UCB SA Jason Gammack, VP and Global Head of Advanced Genomics Commercial Operations, QIAGEN N.V. Stefan Höfer, Vice President, Issuer & Primary Market Relations, Deutsche Börse AG Thomas Klein, CEO, Cytolon AG Dr. jur. Dr. med. Adem Koyuncu, Partner, COVINGTON & BURLING LLP Dr. med. Markus Manns, Senior Equities Fund Manager, Union Investment Privatfonds GmbH Dr. Oliver Müller, Head of Healthcare, Capgemini Consulting
Dr. Markus Müschenich, MPH, Member of the board of directors at the German Association for Internet Medicine, Founder of Concept Health – The Berlin Think Tank for Health Management
Dr. Martin Pöhlchen, Managing Director, Sinfonie Life Science Management GmbH Dr. Sierk Poetting, CFO, BioNTech AG Karlheinz Schmelig, Managing Partner, CREATHOR VENTURE Management GmbH Petra Streng, Solution Manager, SAP SE Ulrich Taibon, Head of Molecular Systems, STRATEC Biomedical AG Prof. Dr. Jörg Vienken, Board Member, Nephro-Solutions AG
uTarget group The conference is geared to company representatives, sector specialists, life science experts as well as practicians
and experts from research institutions.
uParticipation By invitation only. Participation is free of charge.
uVenue DVFA Center Mainzer Landstrasse 37-39 60329 Frankfurt am Main Germany Tel.: +49 (0) 69 24 24 94 08
LIFE SCIENCE_
Conference 16 June 2015, 9 a.m.
Invitation_
LIFE SCIENCEDVFA LIFE SCIENCE CONFERENCE_
08:45 a.m . uCheck-in
09:00 a.m. uWelcome Dr. Christa Bähr, CEFA, CFA, Chairwoman DVFA Life Science Commission, CB HealthCare Ralf Frank, Secretary General, DVFA
09:10 a.m. uIntroduction Dr. Markus Müschenich, MPH, Member of the board of directors at the
German Association for Internet Medicine, Founder of Concept Health – The Berlin Think Tank for Health Management
09:45 a.m. uDeriving medical insights from Big Data - A project report across Health-care and Life Sciences.
Petra Streng, Solutions Manager, Industry Business Unit Life Sciences, SAP Life Sciences
10:20 a.m. uMatching patient genomes to treatment – challenges and opportuni-ties for IT in personalized medicine
Dr. Stephan Brock, Chief Technology Officer (CTO), Molecular Health GmbH
10:50 a.m. uCoffee Break
11:10 a.m. uSequencing data without informatics? As valuable as a chocolate teapot! Jason Gammack, VP and Global Head of Advanced Genomics Commercial
Operations, QIAGEN N.V.
11:40 a.m. uPanel I: Big Data for better Therapies Dr. Stephan Brock, Chief Technology Officer (CTO), Molecular Health GmbH Thomas Klein, CEO, Cytolon AG Dr. Oliver Müller, Head of Healthcare, Capgemini Consulting Ulrich Taibon, Head of Molecular Systems, STRATEC Biomedical AG Moderation: Dr. med Markus Manns, Senior Equities Fund Manager,
Union Investment Privatfonds GmbH
12:40 p.m. uLunch
01:30 p.m. uTailored synthetic messenger RNA (mRNA) therapeutics based on patients' genetic information
Dr. Sierk Poetting, CFO, BioNTech AG
02:05 p.m. uOverview why Big data in healthcare is getting more important and examples how UCB is addressing this.
Herman de Prins, CIO, UCB
02:40 p.m. uA new telematic infrastructure in the German Healthcare system Martin Bumm, Prokurist, medisign GmbH
03:10 p.m. uCoffee Break
03:20 p.m. uAnalysis of patient data clouds to improve clinical therapies Prof. Jörg Vienken, Board Member, Nephro-Solutions AG
03:55 p.m. uThe Deutsche Börse Venture Network Stefan Höfer, Vice President, Issuer & Primary Market Relations, Deutsche Börse AG
04:20 p.m. uPanel II: Big Data in Healthcare at the Capital Markets Kai Brüning, CEFA, Senior Portfolio Manager, apoAsset Management GmbH Dr. Siegfried Bialojahn, Ernst & Young GmbH Dr. Martin Pöhlchen, Managing Director, Sinfonie Life Science Manage-
ment GmbH Karlheinz Schmelig, Managing Partner, CREATHOR VENTURE Management GmbH Moderation: Dr. jur. Dr. med. Adem Koyuncu, Partner, COVINGTON & BUR-
LING LLP
05:20 p.m. uGet-together
Programme 16 June 2015
DVFAKarin WenzelTel.: +49 (0)69 264848 101 Fax: +49 (0)69 264848 489Mail: [email protected]
Content: DVFAPhotos: www.shutterstock.com Subject to modifications. Copyright 2015 DVFA e.V.
Members of the DVFA Life Science Commission
Sascha Alilovic, MorphoSys AG, Martinsried/PlaneggDr. Christa Bähr, CEFA, CFA, Chairwoman, CB HealthCare, FrankfurtDr. Viola Bronsema, BIO Deutschland e.V., BerlinKai Brüning, apo Asset Management GmbH, DüsseldorfInes-Regina Buth, CBA, akampion, BerlinDr. Ralf Emmerich, European Investment Fund, LuxemburgAndreas Heinrichs, Bank Vontobel Europe AG, KölnStefan Höfer, Deutsche Börse AG, EschbornDr. Kai Gregor Klinger, RHÖN-KLINIKUM AG, Bad Neustadt a.d. SaaleDr. jur. Dr. med. Adem Koyuncu, COVINGTON & BURLING LLP, BrüsselDr. Solveigh Karola Mähler, MC SERVICES AG, DüsseldorfDr. med. Markus Manns, Chairman, Union Investment Privatfonds GmbH, FrankfurtDr. Markus Metzger, STADA Arzneimittel AG, Bad VilbelDr. Marie-Luise Roth, DIB Deutsche Industrievereinigung Biotechnologie, FrankfurtDr. Martin Schnee, CBA, CCrA, Schnee Research, MaintalDr. Julia Schüler, CBA, BioMedServices, DarmstadtProf. Dr. Joerg Vienken, Nephro-Solutions AG, Hamburg
DVFA – Society of Investment Professionals in Germany
DVFA is the Society of Investment Professionals in Germany, founded in 1960. Currently, DVFA has more than 1,400 individual members representing over 400 investment firms, banks, asset managers, consultants and counselling businesses. DVFA assures the credibility of the professionals and the integrity of the market by offering internationally recognised qualification programmes, by providing platforms for professional financial communication, and by effective self-regulation.
Via EFFAS, the umbrella organisation of European Analysts Societies, DVFA offers access to a pan-European network with more than 17,000 investment professionals in 27 nati-ons. Via ACIIA, the Association of Certified International Investment Analysts, DVFA is part of a worldwide network of more than 100,000 investment professionals.
